SISRAM MED (01696) announced that effective January 1, 2026, current Executive Director and Board Chairman Mr. Liu Yi will transition to a Non-Executive Director role due to internal group reassignment. He will step down as Chairman, Chairman of the Board Nomination Committee, member of the Board Remuneration Committee, and the company’s authorized representative. Mr. Liu will retain his position as a member of the Nomination Committee.

Current Executive Director and CEO Mr. Lior Moshe DAYAN will assume the roles of Executive Director, Chairman, Chairman of the Nomination Committee, and authorized representative. Due to internal group reassignment, he will no longer serve as CEO.

Current Non-Executive Director Ms. Feng Rongli will join the Remuneration Committee, while current Independent Non-Executive Director Mr. Chen Zhifeng will become a member of the Nomination Committee.

Mr. Eyal BEN DAVID, current Group Global Business President, will take over as CEO. Concurrently, Mr. Li Jiahong, Executive Director and CFO, will serve as Co-CEO.

Mr. Wu Yifang will resign as Non-Executive Director effective January 1, 2026, due to work reassignment. Ms. Caroline Xiaokui JIN has been appointed as a Non-Executive Director, effective the same date.